Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 7% – What’s Next?

Bicara Therapeutics Inc. (NASDAQ:BCAX) shares dropped 7% during trading on Tuesday . The stock traded as low as $14.15 and last traded at $14.29. Approximately 222,907 shares were traded during trading, a decline of 40% from the average daily volume of 373,259 shares. The stock had previously closed at $15.36.

Wall Street Analyst Weigh In

BCAX has been the subject of several research reports. HC Wainwright boosted their price target on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Wedbush reiterated an “outperform” rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $13.01 price objective on shares of Bicara Therapeutics in a research note on Thursday. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $36.50.

Bicara Therapeutics Trading Up 2.6 %

The company’s fifty day moving average is $13.28.

Hedge Funds Weigh In On Bicara Therapeutics

Several large investors have recently bought and sold shares of the business. Spire Wealth Management acquired a new position in shares of Bicara Therapeutics during the 4th quarter worth about $31,000. BNP Paribas Financial Markets purchased a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $32,000. Legal & General Group Plc purchased a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $33,000. Summit Investment Advisors Inc. purchased a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $35,000. Finally, Virtus ETF Advisers LLC purchased a new stake in shares of Bicara Therapeutics in the 4th quarter valued at about $69,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.